Nanjing Pharma-Tech Co., Ltd.
Announcement on the Progress of the "Quality and Return Improvement" Action Plan
The Company and the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free of any false representations, misleading statements, or material omissions.
Nanjing Pharma-Tech Co., Ltd. (hereinafter referred to as the "Company") has formulated the "Quality and Return Improvement" Action Plan to practice the concept of "enhancing development quality and strengthening shareholder returns," improve the Company's standardized operation quality, promote the Company's sustainable development, and protect the interests of all shareholders. This plan is formulated based on the Company's future strategies and operating conditions. For details, please refer to the "Announcement on the 'Quality and Return Improvement' Action Plan" (Announcement No.: 2026-023) disclosed by the Company on the Juchao Information Network on April 22, 2026. Since the formulation and disclosure of the "Quality and Return Improvement" Action Plan, the Company has actively implemented the plan, and the progress of the plan is as follows:
I. Focusing on the Core Business, Building a Solid Foundation for High-Quality Development Driven by Technology
During the reporting period, the Company, focusing on the entire lifecycle needs of drug discovery, drug development, and commercial production, has continued to promote the synergistic development of molecular building blocks, drug discovery services (CRO), drug development and production (CDMO), and new molecular entities (OPC) such as oligonucleotides, peptides, and antibody-drug conjugates. The integrated CRDMO service system covering R&D and commercialization phases has been continuously improved, enhancing core competitiveness. In the first half of 2026, the Company achieved operating income of 1.059 billion yuan, a year-on-year increase of 15.19%; and net profit attributable to shareholders of the listed company was 99.4449 million yuan, a year-on-year increase of 37.17%, with continuous improvement in operating quality.
(I) Continuously Enhancing Integrated CRDMO Service Capabilities
During the reporting period, the Company has continued to improve its integrated service system covering drug discovery, process development, and API and formulation development and production, continuously enhancing project acceptance and delivery capabilities.
During the reporting period, the Company's CRO R&D center completed its relocation and upgrade and was officially put into operation. The R&D space and experimental equipment capacity have been significantly increased, further strengthening the capacity for early-stage R&D project acceptance and R&D response efficiency, providing support for the construction of integrated CRDMO service capabilities.
The Company has continued to strengthen project management, technology transfer, quality control, and cross-departmental collaboration mechanisms, improving the overall execution efficiency from process development and validation to GMP production delivery. During the reporting period, the number of GMP projects served by the Company increased by 28% year-on-year, with 4 new PPQ projects; 2 customer projects received NMPA approval for listing, including one DS/DP integrated project, further demonstrating the Company's comprehensive service capabilities in late-stage project development, production delivery, and registration support.
(II) Continuously Enhancing New Molecular Entity Business Capabilities